Therapeutic area intelligence for KRAS G12C-Positive Non-Small Cell Lung Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Roche →

Assets

Divarasib →

Recent signals(1)

CompetitiveJuly 12, 2026

Divarasib Study Targets KRAS G12C-Positive NSCLC Post-Chemoimmunotherapy

A study is underway to evaluate divarasib's efficacy against standard immunotherapy options in NSCLC patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

KRAS G12C-Positive Non-Small Cell Lung Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.